MeiraGTx Holdings (MGTX) Non-Current Assets (2017 - 2025)
MeiraGTx Holdings (MGTX) reported Non-Current Assets of $142.5 million for Q4 2025, up 4.42% on a YoY basis from $136.5 million in Q4 2024, and down 1.83% quarter-over-quarter from $145.2 million in Q3 2025.
MeiraGTx Holdings (MGTX) Non-Current Assets (2017 - 2025) Analysis & Trends
MeiraGTx Holdings has reported Non-Current Assets for 9 years, with the latest figure at $142.5 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Assets rose 4.42% year-over-year to $142.5 million; the trailing twelve-month figure through Dec 2025 stood at $142.5 million (up 4.42% YoY), and the FY2025 full-year result was $142.5 million, up 4.42% from the prior year.
- Non-Current Assets for Q4 2025 stood at $142.5 million, down from $145.2 million in the prior quarter.
- The five-year high for Non-Current Assets was $167.1 million in Q2 2023, with the low at $109.6 million in Q1 2021.
- Historically, Non-Current Assets has averaged $144.1 million across 5 years, with a median of $145.8 million in 2022.
- Annual changes were most pronounced in 2021 — Non-Current Assets jumped 116.1% — and 2024, when it retreated 13.27%.
- MeiraGTx Holdings' Non-Current Assets stood at $136.9 million in 2021, then grew by 14.06% to $156.2 million in 2022, then grew by 0.76% to $157.4 million in 2023, then declined by 13.27% to $136.5 million in 2024, then advanced by 4.42% to $142.5 million in 2025.
- The last three Non-Current Assets figures came in at $142.5 million (Q4 2025), $145.2 million (Q3 2025), and $141.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | MeiraGTx Holdings | 910.47 Mn | 844.54 Mn | 74.89 Mn | 142.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 142.51 Mn |
| Sep 30, 2025 | 145.17 Mn |
| Jun 30, 2025 | 141.53 Mn |
| Mar 31, 2025 | 134.26 Mn |
| Dec 31, 2024 | 136.47 Mn |
| Sep 30, 2024 | 150.38 Mn |
| Jun 30, 2024 | 146.92 Mn |
| Mar 31, 2024 | 150.97 Mn |
| Dec 31, 2023 | 157.36 Mn |
| Sep 30, 2023 | 154.88 Mn |
| Jun 30, 2023 | 167.12 Mn |
| Mar 31, 2023 | 166.66 Mn |
| Dec 31, 2022 | 156.17 Mn |
| Sep 30, 2022 | 146.38 Mn |
| Jun 30, 2022 | 148.05 Mn |
| Mar 31, 2022 | 144.77 Mn |
| Dec 31, 2021 | 136.92 Mn |
| Sep 30, 2021 | 126.41 Mn |
| Jun 30, 2021 | 119.72 Mn |
| Mar 31, 2021 | 109.55 Mn |